Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.

Epilepsy Clinical Trial

— REMI  

Official title:

Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With REMI.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06027749
• Other study ID #: REMI-23-01
• Status: Recruiting
• Phase: N/A
• Start date: October 13, 2023
• Est. completion date: June 1, 2024

Study information

• Verified date: October 2023
• Source: Epitel, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to test Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days) in patients presenting with questionable seizure characterization. The main questions it aims to answer are: • Can more seizure events be recorded in fourteen (14) days than can be recorded in three (3) days? • Do treating clinicians find clinical value in extended fourteen (14) - twenty-eight (28) days of EEG? Participants will wear a portable EEG device (REMI) for fourteen (14) to twenty-eight (28) days in their home/community setting.

Description:

This is a prospective study to quantify Epitel's™ Remote EEG Monitoring System's (REMI™) ability to record electroencephalography (EEG) of seizure events in an ambulatory setting for extended periods (14 - 28 days). Patients presenting with questionable seizure characterization that are scheduling a conventional at home ambulatory EEG (Amb EEG) and who meet the study inclusion and exclusion criteria will be prescribed a REMI system.

The purpose of this study is to demonstrate that the REMI system is able to record EEG data that clinicians can use to identify ictal events over extended periods, and that extended clinical EEG data is valuable in the diagnosis and treatment of seizure related symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 65
• Est. completion date: June 1, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients have a reported history of seizures (epileptic, non-epileptic, or unknown),

• Have a minimum reported seizure rate of one every two weeks,

• Are prescribed an ambulatory EEG study as part of routine care,

• Is Male or Female between the ages of 18 and 70,

• Can understand and sign written informed consent, or have a legal guardian provide consent,

• The Patient (or Primary Caregiver) must be competent to follow all study procedures,

• The Patient must be willing to use the System for a prolonged period (up to 30 days), for a minimum of 20 hours/day.

Exclusion Criteria:

• Is sensitive or allergic to medical acrylics, silicones, or hydrogels,

• Is enrolled in another investigational drug or device trial,

• Is homeless or in a home without a power supply, or

• Cannot read, speak, or understand English (and does not have a translator).

Related Conditions & MeSH terms

• Epilepsy
• Seizures

Intervention

Device:
• Epitel's™ Remote EEG Monitoring System's (REMI™)
Ambulatory electroencephalography (EEG) monitoring

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Epitel, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ictal Events Identified in fourteen (14) days.	Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first three days will be compared to the number of seizures identified during days one (1) to fourteen (14).	Fourteen (14) days
Secondary	Extended Use	Epileptiform seizure activity as identified by three independent board-certified epileptologists assessing data collected by REMI. The number of seizures identified in the first fourteen (14) days will be compared to the number of seizures identified during all twenty-eight (28) days.	Twenty-eight (28) days